ArticleClinical and translational gastroenterology2026
The Economic Impact of Cirrhosis and Other Chronic Liver Diseases on Global, Regional, and National Economies.
Article in Clinical and translational gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionTo understand the macroeconomic impact of cirrhosis and other chronic liver diseases globally, regionally, and nationally, facilitating rational resource allocation. The authors investigated the macroeconomic consequences associated with the burden of cirrhosis and other chronic liver diseases across 199 countries in 2021.
methodsData on disability-adjusted life years for cirrhosis and other chronic liver diseases, including subtypes such as chronic hepatitis B, chronic hepatitis C, nonalcoholic fatty liver disease (including cirrhosis), cirrhosis due to alcohol, and cirrhosis from other causes, were derived from the 2021 Global Burden of Disease study database. Gross domestic product (GDP) data, adjusted by purchasing power parity, were obtained from the World Bank. The study integrated GDP and disability-adjusted life year data and applied the value of lost welfare approach to quantify macroeconomic losses. All results are reported in 2021 international dollars, adjusted for purchasing power parity.
resultsIn 2021, global value of lost welfare from cirrhosis and chronic liver diseases reached $365.13 billion (0.38% of GDP), with subtypes varying chronic hepatitis B (0.18%, $168.41 billion), hepatitis C (0.08%, $77.09 billion), alcohol-related cirrhosis (0.06%, $58.01 billion), and others. Regional disparities emerged: High-income regions showed the highest overall (3.60%) and hepatitis B (1.42%) ratios, Central/Eastern Europe/Central Asia led in alcohol (0.19%) and other causes (0.08%), Latin America/Caribbean in fatty liver (0.07%), and North Africa/Middle East in hepatitis C (0.13%). DISCUSSION: These diseases impose significant macroeconomic burdens globally and by subtype, justifying prioritized healthcare resource allocation to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.